RXO Form 4: CEO purchases shares at $12.80–$12.89 range
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
RXO, Inc. reported an insider purchase by its Chief Executive Officer and director on 11/10/2025. The filing lists two open‑market buys: 7,775 shares and 3,850 shares. The purchase price ranged from $12.80–$12.89, with a weighted average purchase price of $12.88.
Following these transactions, beneficial ownership is shown in three lines: 7,775 shares held indirectly by a trust, 3,850 shares held directly, and 271,767 shares held indirectly through a limited liability company controlled by the reporting person.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 11,625 shares ($149,422)
Net Buy
3 txns
Insider
Wilkerson Andrew M.
Role
Chief Executive Officer
Bought
11,625 shs ($149K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 7,775 | $12.88 | $100K |
| Purchase | Common Stock | 3,850 | $12.80 | $49K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 7,775 shares (Indirect, By Trust);
Common Stock — 3,850 shares (Direct)
Footnotes (1)
- The purchase price ranged from $12.80 to $12.89, with a weighted average purchase price of $12.88. Upon request, the Reporting Person hereby undertakes to provide to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. The shares are held by a limited liability company that is controlled by the Reporting Person.
FAQ
What insider transaction did RXO (RXO) report?
The CEO and director reported open‑market purchases on 11/10/2025 totaling two trades of 7,775 and 3,850 common shares.
What was the transaction code in the RXO Form 4?
Both entries are coded P, indicating open‑market or private purchase of non‑derivative securities.
Does the filing mention how indirect holdings are structured?
Yes. 7,775 shares are held by a trust, and 271,767 shares are held by a limited liability company controlled by the reporting person.
Were any derivative securities involved in this RXO filing?
No derivative securities are listed; Table II contains no entries.